{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T07:53:40Z","timestamp":1790409220066,"version":"4.1.0"},"reference-count":138,"publisher":"Frontiers Media SA","funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 HL133191, R01 HL131093, R01 AI51390, and R01 HL097088"],"award-info":[{"award-number":["R01 HL133191, R01 HL131093, R01 AI51390, and R01 HL097088"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007659","name":"Bayer Corporation","doi-asserted-by":"publisher","award":["Early Career Investigator Award"],"award-info":[{"award-number":["Early Career Investigator Award"]}],"id":[{"id":"10.13039\/100007659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2017.01604","type":"journal-article","created":{"date-parts":[[2017,11,24]],"date-time":"2017-11-24T04:13:29Z","timestamp":1511496809000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":29,"title":["Innovative Approaches for Immune Tolerance to Factor VIII in the Treatment of Hemophilia A"],"prefix":"10.3389","volume":"8","author":[{"given":"Alexandra","family":"Sherman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moanaro","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland W.","family":"Herzog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2017,11,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2147\/JBM.S77332","article-title":"Acquired hemophilia A: emerging treatment options","volume":"6","author":"Janbain","year":"2015","journal-title":"J Blood Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1182\/asheducation-2012.1.362","article-title":"New challenges in hemophilia: long-term outcomes and complications","volume":"2012","author":"Young","year":"2012","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"B3","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1055\/s-0037-1615621","article-title":"Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis","volume":"85","author":"White","year":"2001","journal-title":"Thromb Haemost"},{"key":"B4","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1182\/blood-2013-12-530113","article-title":"The intron-22-inverted F8 locus permits factor VIII synthesis: explanation for low inhibitor risk and a role for pharmacogenomics","volume":"125","author":"Sauna","year":"2015","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/j.1365-2516.2006.01361.x","article-title":"Genetic risk factors for inhibitors to factors VIII and IX","volume":"12","author":"Oldenburg","year":"2006","journal-title":"Haemophilia"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1182\/blood-2014-02-546127","article-title":"Molecular and clinical predictors of inhibitor risk and its prevention and treatment in mild hemophilia A","volume":"124","author":"Castaman","year":"2014","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/hae.12989","article-title":"Innovating immune tolerance induction for haemophilia","volume":"22","author":"Batsuli","year":"2016","journal-title":"Haemophilia"},{"key":"B8","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1056\/NEJMoa067659","article-title":"Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia","volume":"357","author":"Manco-Johnson","year":"2007","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"366","DOI":"10.2450\/2011.0092-10","article-title":"Factor VIII safety: plasma-derived versus recombinant products","volume":"9","author":"Gringeri","year":"2011","journal-title":"Blood Transfus"},{"key":"B10","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/hae.13028","article-title":"Extended half-life clotting factor concentrates: results from published clinical trials","volume":"22","author":"Young","year":"2016","journal-title":"Haemophilia"},{"key":"B11","doi-asserted-by":"publisher","first-page":"187","DOI":"10.2147\/JBM.S80814","article-title":"Therapeutic and routine prophylactic properties of rFactor VIII Fc (efraloctocog alfa, Eloctate(R)) in hemophilia A","volume":"7","author":"Chowdary","year":"2016","journal-title":"J Blood Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"3024","DOI":"10.1182\/blood-2011-08-367813","article-title":"Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs","volume":"119","author":"Dumont","year":"2012","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1182\/blood-2013-10-529974","article-title":"Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A","volume":"123","author":"Mahlangu","year":"2014","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1182\/blood-2015-03-630897","article-title":"Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A","volume":"126","author":"Konkle","year":"2015","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1111\/hae.12159","article-title":"Results from a large multinational clinical trial (guardian1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy","volume":"19","author":"Lentz","year":"2013","journal-title":"Haemophilia"},{"key":"B16","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/bjh.13797","article-title":"New products for the treatment of haemophilia","volume":"172","author":"Laffan","year":"2016","journal-title":"Br J Haematol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.cellimm.2015.12.008","article-title":"Recombinant factor VIII Fc (rFVIIIFc) fusion protein reduces immunogenicity and induces tolerance in hemophilia A mice","volume":"301","author":"Krishnamoorthy","year":"2016","journal-title":"Cell Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1056\/NEJMoa1511769","article-title":"Factor VIII-mimetic function of humanized bispecific antibody in hemophilia A","volume":"374","author":"Shima","year":"2016","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1182\/blood-2015-06-650226","article-title":"A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects","volume":"127","author":"Uchida","year":"2016","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1160\/TH17-01-0030","article-title":"Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX\/IXa and X\/Xa, emicizumab, depends on its ability to bridge the antigens","volume":"117","author":"Kitazawa","year":"2017","journal-title":"Thromb Haemost"},{"key":"B21","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1056\/NEJMoa1611925","article-title":"Targeting of antithrombin in hemophilia A or B with RNAi therapy","volume":"377","author":"Pasi","year":"2017","journal-title":"N Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/j.ymthe.2017.03.033","article-title":"Gene therapy for hemophilia","volume":"25","author":"Nienhuis","year":"2017","journal-title":"Mol Ther"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/jcm6050054","article-title":"Hemophilia care in the pediatric age","volume":"6","author":"Bertamino","year":"2017","journal-title":"J Clin Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"6367","DOI":"10.1182\/blood-2010-09-308668","article-title":"Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom","volume":"117","author":"Hay","year":"2011","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1177\/2040620712464509","article-title":"Factor VIII inhibitors in hemophilia A: rationale and latest evidence","volume":"4","author":"Witmer","year":"2013","journal-title":"Ther Adv Hematol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1182\/blood-2014-08-535328","article-title":"FVIII inhibitors: pathogenesis and avoidance","volume":"125","author":"Astermark","year":"2015","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1182\/blood-2008-06-160432","article-title":"How we treat a hemophilia A patient with a factor VIII inhibitor","volume":"113","author":"Kempton","year":"2009","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1097\/MBC.0000000000000647","article-title":"Meta-analysis on incidence of inhibitors in patients with haemophilia A treated with recombinant factor VIII products","author":"Rota","year":"2017","journal-title":"Blood Coagul Fibrinolysis"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1182\/blood-2015-11-682468","article-title":"T cells from hemophilia A subjects recognize the same HLA-restricted FVIII epitope with a narrow TCR repertoire","volume":"128","author":"Ettinger","year":"2016","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1182\/blood-2008-01-128413","article-title":"Transient blockade of the inducible costimulator pathway generates long-term tolerance to factor VIII after nonviral gene transfer into hemophilia A mice","volume":"112","author":"Peng","year":"2008","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1182\/blood-2008-04-151597","article-title":"Anti-CD3 prevents factor VIII inhibitor development in hemophilia A mice by a regulatory CD4+CD25+-dependent mechanism and by shifting cytokine production to favor a Th1 response","volume":"113","author":"Waters","year":"2009","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1111\/j.1538-7836.2009.03571.x","article-title":"Splenic marginal zone antigen-presenting cells are critical for the primary allo-immune response to therapeutic factor VIII in hemophilia A","volume":"7","author":"Navarrete","year":"2009","journal-title":"J Thromb Haemost"},{"key":"B33","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1182\/blood-2010-06-289009","article-title":"Stimulation and inhibition of FVIII-specific memory B-cell responses by CpG-B (ODN 1826), a ligand for toll-like receptor 9","volume":"117","author":"Allacher","year":"2011","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","first-page":"3154","DOI":"10.1182\/blood-2011-02-336198","article-title":"T cell-independent restimulation of FVIII-specific murine memory B cells is facilitated by dendritic cells together with toll-like receptor 7 agonist","volume":"118","author":"Pordes","year":"2011","journal-title":"Blood"},{"key":"B35","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/bjh.12028","article-title":"Immune tolerance in haemophilia: the long journey to the fork in the road","volume":"159","author":"DiMichele","year":"2012","journal-title":"Br J Haematol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"s319","DOI":"10.2450\/2013.0246-12","article-title":"Key issues in inhibitor management in patients with haemophilia","volume":"12","author":"Gomez","year":"2014","journal-title":"Blood Transfus"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1111\/j.1538-7836.2009.03538.x","article-title":"The molecular mechanisms of immunomodulation and tolerance induction to factor VIII","volume":"7","author":"Waters","year":"2009","journal-title":"J Thromb Haemost"},{"key":"B38","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1016\/j.thromres.2010.10.006","article-title":"Immune tolerance induction in patients with hemophilia A","volume":"127","author":"Astermark","year":"2011","journal-title":"Thromb Res"},{"key":"B39","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1111\/j.1538-7836.2011.04349.x","article-title":"Immune tolerance induction in haemophilia: evidence and the way forward","volume":"9","author":"Di Michele","year":"2011","journal-title":"J Thromb Haemost"},{"key":"B40","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1111\/j.1538-7836.2009.03417.x","article-title":"Role of regulatory T cells in tolerance to coagulation factors","volume":"7","author":"Cao","year":"2009","journal-title":"J Thromb Haemost"},{"key":"B41","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1586\/ehm.10.33","article-title":"Immunomodulation for inhibitors in hemophilia A: the important role of Treg cells","volume":"3","author":"Miao","year":"2010","journal-title":"Expert Rev Hematol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.cellimm.2015.10.001","article-title":"In vivo induction of regulatory T cells for immune tolerance in hemophilia","volume":"301","author":"Wang","year":"2016","journal-title":"Cell Immunol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.immuni.2013.03.002","article-title":"Development and maintenance of regulatory T cells","volume":"38","author":"Ohkura","year":"2013","journal-title":"Immunity"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1111\/j.1538-7836.2009.03548.x","article-title":"Prophylactic immune tolerance induced by changing the ratio of antigen-specific effector to regulatory T cells","volume":"7","author":"Nayak","year":"2009","journal-title":"J Thromb Haemost"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1111\/j.1538-7836.2011.04351.x","article-title":"Induction of tolerance to factor VIII by transient co-administration with rapamycin","volume":"9","author":"Moghimi","year":"2011","journal-title":"J Thromb Haemost"},{"key":"B46","doi-asserted-by":"publisher","first-page":"E156","DOI":"10.1073\/pnas.1408686111","article-title":"Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance","volume":"112","author":"Maldonado","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B47","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.cellimm.2015.11.004","article-title":"Tolerogenic nanoparticles to induce immunologic tolerance: prevention and reversal of FVIII inhibitor formation","volume":"301","author":"Zhang","year":"2016","journal-title":"Cell Immunol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"2937","DOI":"10.1182\/blood-2014-09-599266","article-title":"Synergy between rapamycin and FLT3 ligand enhances plasmacytoid dendritic cell-dependent induction of CD4+CD25+FoxP3+ Treg","volume":"125","author":"Biswas","year":"2015","journal-title":"Blood"},{"key":"B49","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1038\/ni.2370","article-title":"Deciphering the transcriptional network of the dendritic cell lineage","volume":"13","author":"Miller","year":"2012","journal-title":"Nat Immunol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"3766","DOI":"10.1172\/JCI81859","article-title":"IDO1 suppresses inhibitor development in hemophilia A treated with factor VIII","volume":"125","author":"Matino","year":"2015","journal-title":"J Clin Invest"},{"key":"B51","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1084\/jem.20082824","article-title":"In vivo expansion of T reg cells with IL-2-mAb complexes: induction of resistance to EAE and long-term acceptance of islet allografts without immunosuppression","volume":"206","author":"Webster","year":"2009","journal-title":"J Exp Med"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1038\/mt.2011.61","article-title":"In vivo expansion of regulatory T cells with IL-2\/IL-2 mAb complexes prevents anti-factor VIII immune responses in hemophilia A mice treated with factor VIII plasmid-mediated gene therapy","volume":"19","author":"Liu","year":"2011","journal-title":"Mol Ther"},{"key":"B53","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1111\/jth.12576","article-title":"Long-term tolerance to factor VIII is achieved by administration of interleukin-2\/interleukin-2 monoclonal antibody complexes and low dosages of factor VIII","volume":"12","author":"Liu","year":"2014","journal-title":"J Thromb Haemost"},{"key":"B54","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.smim.2011.07.008","article-title":"Clinical perspectives for regulatory T cells in transplantation tolerance","volume":"23","author":"Hippen","year":"2011","journal-title":"Semin Immunol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.omtm.2016.12.003","article-title":"Expansion of human tregs from cryopreserved umbilical cord blood for GMP-compliant autologous adoptive cell transfer therapy","volume":"4","author":"Seay","year":"2017","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B56","doi-asserted-by":"publisher","first-page":"14030","DOI":"10.1038\/mtm.2014.30","article-title":"Ex vivo expanded autologous polyclonal regulatory T cells suppress inhibitor formation in hemophilia","volume":"1","author":"Sarkar","year":"2014","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B57","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1172\/JCI76031","article-title":"Selective Treg reconstitution during lymphopenia normalizes DC costimulation and prevents graft-versus-host disease","volume":"125","author":"Bolton","year":"2015","journal-title":"J Clin Invest"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1182\/blood-2014-04-566786","article-title":"Engineered antigen-specific human regulatory T cells: immunosuppression of FVIII-specific T- and B-cell responses","volume":"125","author":"Kim","year":"2015","journal-title":"Blood"},{"key":"B59","doi-asserted-by":"publisher","first-page":"16015","DOI":"10.1038\/mto.2016.15","article-title":"Clinical manufacturing of CAR T cells: foundation of a promising therapy","volume":"3","author":"Wang","year":"2016","journal-title":"Mol Ther Oncolytics"},{"key":"B60","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.omtm.2016.12.006","article-title":"Global manufacturing of CAR T cell therapy","volume":"4","author":"Levine","year":"2017","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B61","doi-asserted-by":"publisher","first-page":"16034","DOI":"10.1038\/mtm.2016.34","article-title":"Clinical development of gene therapy: results and lessons from recent successes","volume":"3","author":"Kumar","year":"2016","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B62","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.trsl.2017.06.002","article-title":"Hemophilia A inhibitor treatment: the promise of engineered T-cell therapy","volume":"187","author":"Parvathaneni","year":"2017","journal-title":"Transl Res"},{"key":"B63","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1182\/blood-2016-07-727834","article-title":"FVIII-specific human chimeric antigen receptor T-regulatory cells suppress T- and B-cell responses to FVIII","volume":"129","author":"Yoon","year":"2017","journal-title":"Blood"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1002\/eji.201141649","article-title":"Transduced B cells: B is for \u2018beneficial\u2019!","volume":"41","author":"Scott","year":"2011","journal-title":"Eur J Immunol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"369","DOI":"10.2174\/156652307782151443","article-title":"Tolerance induction by gene transfer to lymphocytes","volume":"7","author":"Skupsky","year":"2007","journal-title":"Curr Gene Ther"},{"key":"B66","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1038\/mt.2014.43","article-title":"Immune tolerance induction to factor IX through B cell gene transfer: TLR9 signaling delineates between tolerogenic and immunogenic B cells","volume":"22","author":"Wang","year":"2014","journal-title":"Mol Ther"},{"key":"B67","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.omtm.2017.03.005","article-title":"Immune modulatory cell therapy for hemophilia B based on CD20-targeted lentiviral gene transfer to primary B cells","volume":"5","author":"Wang","year":"2017","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B68","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1038\/mt.2010.95","article-title":"B-cell-delivered gene therapy induces functional T regulatory cells and leads to a loss of antigen-specific effector cells","volume":"18","author":"Skupsky","year":"2010","journal-title":"Mol Ther"},{"key":"B69","doi-asserted-by":"publisher","first-page":"4865","DOI":"10.1182\/blood-2004-11-4274","article-title":"Induction of tolerance to factor VIII inhibitors by gene therapy with immunodominant A2 and C2 domains presented by B cells as Ig fusion proteins","volume":"105","author":"Lei","year":"2005","journal-title":"Blood"},{"key":"B70","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/j.1365-2516.2005.01170.x","article-title":"Rituximab for congenital haemophiliacs with inhibitors: a Canadian experience","volume":"12","author":"Carcao","year":"2006","journal-title":"Haemophilia"},{"key":"B71","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1160\/TH14-01-0078","article-title":"Rituximab for treatment of inhibitors in haemophilia A. A Phase II study","volume":"112","author":"Leissinger","year":"2014","journal-title":"Thromb Haemost"},{"key":"B72","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1160\/TH16-05-0404","article-title":"Combination therapy for inhibitor reversal in haemophilia A using monoclonal anti-CD20 and rapamycin","volume":"117","author":"Biswas","year":"2017","journal-title":"Thromb Haemost"},{"key":"B73","doi-asserted-by":"publisher","first-page":"e37671","DOI":"10.1371\/journal.pone.0037671","article-title":"Transient B cell depletion or improved transgene expression by codon optimization promote tolerance to factor VIII in gene therapy","volume":"7","author":"Sack","year":"2012","journal-title":"PLoS One"},{"key":"B74","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","article-title":"Long-term safety and efficacy of factor IX gene therapy in hemophilia B","volume":"371","author":"Nathwani","year":"2014","journal-title":"N Engl J Med"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2017.05.006","article-title":"Complexity of immune responses to AAV transgene products \u2013 example of factor IX","author":"Herzog","year":"2017","journal-title":"Cell Immunol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1089\/hum.2017.167","article-title":"Advances in gene therapy for haemophilia","volume":"28","author":"Nathwani","year":"2017","journal-title":"Hum Gene Ther"},{"key":"B77","doi-asserted-by":"publisher","first-page":"849","DOI":"10.3324\/haematol.2015.129858","article-title":"The search for the origin of factor VIII synthesis and its impact on therapeutic strategies for hemophilia A","volume":"100","author":"Arruda","year":"2015","journal-title":"Haematologica"},{"key":"B78","doi-asserted-by":"publisher","first-page":"14013","DOI":"10.1038\/mtm.2014.13","article-title":"Development of gene transfer for induction of antigen-specific tolerance","volume":"1","author":"Sack","year":"2014","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B79","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1172\/JCI200316887","article-title":"Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer","volume":"111","author":"Mingozzi","year":"2003","journal-title":"J Clin Invest"},{"key":"B80","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1002\/emmm.201302859","article-title":"Effective gene therapy for haemophilic mice with pathogenic factor IX antibodies","volume":"5","author":"Markusic","year":"2013","journal-title":"EMBO Mol Med"},{"key":"B81","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1182\/blood-2004-03-0847","article-title":"Induction of antigen-specific CD4+ T-cell anergy and deletion by in vivo viral gene transfer","volume":"104","author":"Dobrzynski","year":"2004","journal-title":"Blood"},{"key":"B82","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1038\/mt.2013.94","article-title":"The role of apoptosis in immune hyporesponsiveness following AAV8 liver gene transfer","volume":"21","author":"Faust","year":"2013","journal-title":"Mol Ther"},{"key":"B83","doi-asserted-by":"publisher","first-page":"4592","DOI":"10.1073\/pnas.0508685103","article-title":"Prevention of cytotoxic T lymphocyte responses to factor IX-expressing hepatocytes by gene transfer-induced regulatory T cells","volume":"103","author":"Dobrzynski","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B84","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1182\/blood-2007-02-073304","article-title":"Induction and role of regulatory CD4+CD25+ T cells in tolerance to the transgene product following hepatic in vivo gene transfer","volume":"110","author":"Cao","year":"2007","journal-title":"Blood"},{"key":"B85","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1182\/blood-2007-03-080093","article-title":"Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver","volume":"110","author":"Mingozzi","year":"2007","journal-title":"Blood"},{"key":"B86","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1038\/mt.2011.33","article-title":"Nonredundant roles of IL-10 and TGF-beta in suppression of immune responses to hepatic AAV-factor IX gene transfer","volume":"19","author":"Hoffman","year":"2011","journal-title":"Mol Ther"},{"key":"B87","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/intimm\/dxq001","article-title":"GITR engagement preferentially enhances proliferation of functionally competent CD4+CD25+FoxP3+ regulatory T cells","volume":"22","author":"Liao","year":"2010","journal-title":"Int Immunol"},{"key":"B88","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3389\/fimmu.2014.00035","article-title":"Glucocorticoid-induced TNF receptor family-related protein ligand is requisite for optimal functioning of regulatory CD4(+) T cells","volume":"5","author":"Liao","year":"2014","journal-title":"Front Immunol"},{"key":"B89","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1038\/nri2858","article-title":"Antigen-presenting cell function in the tolerogenic liver environment","volume":"10","author":"Thomson","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"16083","DOI":"10.1038\/mtm.2016.83","article-title":"Dynamics of antigen presentation to transgene product-specific CD4+ T cells and of Treg induction upon hepatic AAV gene transfer","volume":"3","author":"Perrin","year":"2016","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B91","doi-asserted-by":"publisher","first-page":"16064","DOI":"10.1038\/mtm.2016.64","article-title":"Overexpression of factor VIII after AAV delivery is transiently associated with cellular stress in hemophilia A mice","volume":"3","author":"Lange","year":"2016","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B92","doi-asserted-by":"publisher","first-page":"16063","DOI":"10.1038\/mtm.2016.63","article-title":"Potential for cellular stress response to hepatic factor VIII expression from AAV vector","volume":"3","author":"Zolotukhin","year":"2016","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B93","doi-asserted-by":"publisher","first-page":"5842","DOI":"10.1182\/blood-2010-06-288001","article-title":"Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy","volume":"116","author":"Finn","year":"2010","journal-title":"Blood"},{"key":"B94","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/mt.2010.240","article-title":"Efficacy and safety of long-term prophylaxis in severe hemophilia A dogs following liver gene therapy using AAV vectors","volume":"19","author":"Sabatino","year":"2011","journal-title":"Mol Ther"},{"key":"B95","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1111\/jth.13331","article-title":"Gene therapy for immune tolerance induction in hemophilia with inhibitors","volume":"14","author":"Arruda","year":"2016","journal-title":"J Thromb Haemost"},{"key":"B96","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1002\/hep.24230","article-title":"Hepatocyte-targeted expression by integrase-defective lentiviral vectors induces antigen-specific tolerance in mice with low genotoxic risk","volume":"53","author":"Matrai","year":"2011","journal-title":"Hepatology"},{"key":"B97","doi-asserted-by":"publisher","first-page":"2797","DOI":"10.1182\/blood-2006-10-049312","article-title":"In vivo administration of lentiviral vectors triggers a type I interferon response that restricts hepatocyte gene transfer and promotes vector clearance","volume":"109","author":"Brown","year":"2007","journal-title":"Blood"},{"key":"B98","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1038\/mt.2012.150","article-title":"A TLR and non-TLR mediated innate response to lentiviruses restricts hepatocyte entry and can be ameliorated by pharmacological blockade","volume":"20","author":"Agudo","year":"2012","journal-title":"Mol Ther"},{"key":"B99","doi-asserted-by":"publisher","first-page":"4144","DOI":"10.1182\/blood-2007-03-078493","article-title":"A microRNA-regulated lentiviral vector mediates stable correction of hemophilia B mice","volume":"110","author":"Brown","year":"2007","journal-title":"Blood"},{"key":"B100","doi-asserted-by":"publisher","first-page":"5152","DOI":"10.1182\/blood-2009-04-214569","article-title":"In vivo delivery of a microRNA-regulated transgene induces antigen-specific regulatory T cells and promotes immunologic tolerance","volume":"114","author":"Annoni","year":"2009","journal-title":"Blood"},{"key":"B101","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/mt.2010.290","article-title":"A microRNA-regulated and GP64-pseudotyped lentiviral vector mediates stable expression of FVIII in a murine model of hemophilia A","volume":"19","author":"Matsui","year":"2011","journal-title":"Mol Ther"},{"key":"B102","doi-asserted-by":"publisher","first-page":"277ra228","DOI":"10.1126\/scitranslmed.aaa1405","article-title":"Liver-directed lentiviral gene therapy in a dog model of hemophilia B","volume":"7","author":"Cantore","year":"2015","journal-title":"Sci Transl Med"},{"key":"B103","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1016\/j.ymthe.2017.06.001","article-title":"Micromanaging tolerance in hemophilia A gene therapy","volume":"25","author":"Jobson","year":"2017","journal-title":"Mol Ther"},{"key":"B104","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1016\/j.ymthe.2017.04.029","article-title":"A novel platform for immune tolerance induction in hemophilia A mice","volume":"25","author":"Merlin","year":"2017","journal-title":"Mol Ther"},{"key":"B105","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.addr.2012.10.013","article-title":"Mechanism of oral tolerance induction to therapeutic proteins","volume":"65","author":"Wang","year":"2013","journal-title":"Adv Drug Deliv Rev"},{"key":"B106","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1126\/science.aaf2167","article-title":"Immunology. How does the immune system tolerate food?","volume":"351","author":"Kuhn","year":"2016","journal-title":"Science"},{"key":"B107","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.smim.2017.07.001","article-title":"Oral tolerance and allergy","volume":"30","author":"Hamad","year":"2017","journal-title":"Semin Immunol"},{"key":"B108","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.smim.2017.07.008","article-title":"Clinical aspects of oral immunotherapy for the treatment of allergies","volume":"30","author":"Yanagida","year":"2017","journal-title":"Semin Immunol"},{"key":"B109","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1146\/annurev.med.48.1.341","article-title":"Oral tolerance for the treatment of autoimmune diseases","volume":"48","author":"Weiner","year":"1997","journal-title":"Annu Rev Med"},{"key":"B110","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1111\/j.1600-065X.2011.01017.x","article-title":"Oral tolerance","volume":"241","author":"Weiner","year":"2011","journal-title":"Immunol Rev"},{"key":"B111","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/nature16962","article-title":"Expanding antigen-specific regulatory networks to treat autoimmunity","volume":"530","author":"Clemente-Casares","year":"2016","journal-title":"Nature"},{"key":"B112","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1196\/annals.1309.053","article-title":"Current issues in the treatment of human diseases by mucosal tolerance","volume":"1029","author":"Weiner","year":"2004","journal-title":"Ann N Y Acad Sci"},{"key":"B113","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/j.jaci.2016.02.004","article-title":"Molecular and cellular mechanisms of food allergy and food tolerance","volume":"137","author":"Chinthrajah","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"B114","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/nri1057","article-title":"Anatomical basis of tolerance and immunity to intestinal antigens","volume":"3","author":"Mowat","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"B115","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/nri3738","article-title":"Regional specialization within the intestinal immune system","volume":"14","author":"Mowat","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"B116","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.it.2011.06.003","article-title":"Intestinal CD103+ dendritic cells: master regulators of tolerance?","volume":"32","author":"Scott","year":"2011","journal-title":"Trends Immunol"},{"key":"B117","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.1002\/eji.201646359","article-title":"Plasmacytoid dendritic cells induce tolerance predominantly by cargoing antigen to lymph nodes","volume":"46","author":"Kohli","year":"2016","journal-title":"Eur J Immunol"},{"key":"B118","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1080\/00365521.2017.1349173","article-title":"Mucosal immune system of the gastrointestinal tract: maintaining balance between the good and the bad","volume":"52","author":"Ahluwalia","year":"2017","journal-title":"Scand J Gastroenterol"},{"key":"B119","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1111\/j.1538-7836.2006.02118.x","article-title":"Induction of partial immune tolerance to factor VIII through prior mucosal exposure to the factor VIII C2 domain","volume":"4","author":"Rawle","year":"2006","journal-title":"J Thromb Haemost"},{"key":"B120","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1006\/jmbi.2001.4921","article-title":"Expression of the native cholera toxin B subunit gene and assembly as functional oligomers in transgenic tobacco chloroplasts","volume":"311","author":"Daniell","year":"2001","journal-title":"J Mol Biol"},{"key":"B121","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1385\/1-59259-7742:365","article-title":"Engineering the chloroplast genome for hyperexpression of human therapeutic proteins and vaccine antigens","volume":"267","author":"Kumar","year":"2004","journal-title":"Methods Mol Biol"},{"key":"B122","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1002\/biot.200600145","article-title":"Production of biopharmaceuticals and vaccines in plants via the chloroplast genome","volume":"1","author":"Daniell","year":"2006","journal-title":"Biotechnol J"},{"key":"B123","doi-asserted-by":"publisher","first-page":"7101","DOI":"10.1073\/pnas.0912181107","article-title":"Oral delivery of bioencapsulated coagulation factor IX prevents inhibitor formation and fatal anaphylaxis in hemophilia B mice","volume":"107","author":"Verma","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B124","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1182\/blood-2013-10-528737","article-title":"Suppression of inhibitor formation against FVIII in a murine model of hemophilia A by oral delivery of antigens bioencapsulated in plant cells","volume":"124","author":"Sherman","year":"2014","journal-title":"Blood"},{"key":"B125","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.1182\/blood-2014-08-597070","article-title":"Plant-based oral tolerance to hemophilia therapy employs a complex immune regulatory response including LAP+CD4+ T cells","volume":"125","author":"Wang","year":"2015","journal-title":"Blood"},{"key":"B126","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1111\/j.1467-7652.2007.00259.x","article-title":"Expression of cholera toxin B-proinsulin fusion protein in lettuce and tobacco chloroplasts \u2013 oral administration protects against development of insulitis in non-obese diabetic mice","volume":"5","author":"Ruhlman","year":"2007","journal-title":"Plant Biotechnol J"},{"key":"B127","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.biomaterials.2015.08.004","article-title":"Low cost industrial production of coagulation factor IX bioencapsulated in lettuce cells for oral tolerance induction in hemophilia B","volume":"70","author":"Su","year":"2015","journal-title":"Biomaterials"},{"key":"B128","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1104\/pp.16.00981","article-title":"Codon optimization to enhance expression yields insights into chloroplast translation","volume":"172","author":"Kwon","year":"2016","journal-title":"Plant Physiol"},{"key":"B129","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.ymthe.2016.11.009","article-title":"Oral tolerance induction in hemophilia B dogs fed with transplastomic lettuce","volume":"25","author":"Herzog","year":"2017","journal-title":"Mol Ther"},{"key":"B130","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.biomaterials.2016.07.042","article-title":"Topical delivery of low-cost protein drug candidates made in chloroplasts for biofilm disruption and uptake by oral epithelial cells","volume":"105","author":"Liu","year":"2016","journal-title":"Biomaterials"},{"key":"B131","doi-asserted-by":"publisher","first-page":"179","DOI":"10.2174\/187152806778256034","article-title":"Oral tolerance and TGF-beta-producing cells","volume":"5","author":"Faria","year":"2006","journal-title":"Inflamm Allergy Drug Targets"},{"key":"B132","doi-asserted-by":"publisher","first-page":"275ra221","DOI":"10.1126\/scitranslmed.aaa1957","article-title":"Regulation of immune responses to protein therapeutics by transplacental induction of T cell tolerance","volume":"7","author":"Gupta","year":"2015","journal-title":"Sci Transl Med"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1016\/j.siny.2017.05.003","article-title":"Fetal stem cell and gene therapy","author":"Witt","year":"2017","journal-title":"Semin Fetal Neonatal Med"},{"key":"B134","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1111\/jth.12723","article-title":"Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels","volume":"12","author":"Shapiro","year":"2014","journal-title":"J Thromb Haemost"},{"key":"B135","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1038\/gt.2011.200","article-title":"AAV-based neonatal gene therapy for hemophilia A: long-term correction and avoidance of immune responses in mice","volume":"19","author":"Hu","year":"2012","journal-title":"Gene Ther"},{"key":"B136","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.1182\/blood-2008-02-138214","article-title":"Syngeneic transplantation of hematopoietic stem cells that are genetically modified to express factor VIII in platelets restores hemostasis to hemophilia A mice with preexisting FVIII immunity","volume":"112","author":"Shi","year":"2008","journal-title":"Blood"},{"key":"B137","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1038\/ncomms3773","article-title":"Platelet-targeted gene therapy with human factor VIII establishes haemostasis in dogs with haemophilia A","volume":"4","author":"Du","year":"2013","journal-title":"Nat Commun"},{"key":"B138","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1111\/jth.13800","article-title":"Immune tolerance induced by platelet-targeted factor VIII gene therapy in hemophilia A mice is CD4 T cell mediated","volume":"15","author":"Chen","year":"2017","journal-title":"J Thromb Haemost"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fimmu.2017.01604\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,6]],"date-time":"2019-10-06T18:41:38Z","timestamp":1570387298000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fimmu.2017.01604\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,24]]},"references-count":138,"alternative-id":["10.3389\/fimmu.2017.01604"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2017.01604","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,24]]},"article-number":"1604"}}